I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmablast | 5 studies | 35% ± 21% | |
| endothelial cell | 5 studies | 23% ± 11% | |
| epithelial cell | 5 studies | 36% ± 13% | |
| CD8-positive, alpha-beta T cell | 5 studies | 31% ± 11% | |
| B cell | 4 studies | 22% ± 5% | |
| transit amplifying cell | 4 studies | 29% ± 7% | |
| erythroblast | 4 studies | 38% ± 17% | |
| erythrocyte | 4 studies | 31% ± 16% | |
| natural killer cell | 4 studies | 30% ± 8% | |
| CD4-positive, alpha-beta T cell | 4 studies | 40% ± 8% | |
| hematopoietic precursor cell | 3 studies | 28% ± 9% | |
| connective tissue cell | 3 studies | 21% ± 4% | |
| ciliated cell | 3 studies | 24% ± 2% | |
| T cell | 3 studies | 22% ± 5% | |
| dendritic cell | 3 studies | 26% ± 5% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 23% ± 6% |
